Major Pimavanserin should be avoided in combination with ondansetron. Observed without definitive evidence of persistent clinical sequelae. Bepridil should not be given with other drugs that may prolong the QT interval.
Vardenafil is associated with QT prolongation.
Ondansetron is also associated with dose-related QT prolongation; additionally, there are postmarketing reports of torsade de pointes TdP. This website also contains material copyrighted by 3rd parties. If ondansetron and fluconazole are administered together, extreme caution and careful monitoring is advised, especially if higher doses are used or if other drugs that may affect CYP1A2 or CYP2D6 are also given.
Hydroxychloroquine increases the QT interval and should not be administered with other drugs known to prolong the QT interval. Moderate The plasma concentrations of oxybutynin may be elevated when administered concurrently with cobicistat. Dilution is stable for 48 hours at room temperature. Ondansetron doses included 8 mg and 32 mg infused intravenously over 15 minutes.
Dosing & Uses
In Junethe FDA announced preliminary results from a study suggesting that intravenous IV ondansetron given as a single 32 mg dose causes QT prolongation.
Ondansetron is also a weak antagonist of the 5-HT1B, 5-HT1C, alpha-adrenergic, and opioid mu receptors; the clinical implications of these actions is uncertain. Ondansetron has been associated with QT prolongation and post-marketing reports of TdP.
TdP and sudden death have been reported in patients receiving vandetanib; ondansetron also has a possible risk for QT prolongation.
Use ondansetron with caution in patients with cardiac disease or other conditions that may increase the risk of QT prolongation including cardiac arrhythmias, heart failure, bradycardia, myocardial infarction, hypertension, coronary artery disease, hypomagnesemia, hypokalemia, hypocalcemia, or in patients receiving medications known to cause electrolyte imbalances.
Print without Office Info. Median time to first emetic episode h. In one study with 1, infants born to women who reported the use of ondansetron or received an ondansetron prescription in the first trimester, no increased risk for major congenital malformations was seen in aggregate analysis.
Ondansetron is a 5-HT3 receptor antagonist. A study in patients with severe renal impairment who required regular haemodialysis studied between dialyses showed ondansetron's pharmacokinetics to be essentially unchanged following IV administration.
Ondansetron was significantly more effective than placebo in preventing nausea and vomiting. Minor Monitor for altered response to ondansetron during coadministration of rifabutin. Oral disintegrating tablets ODT: Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. Storage Store at room temperature or refrigerate Protect from light, excessive heat, and freezing.